What happens when you take cannabis with SSRIs?
Selective serotonin reuptake inhibitors (SSRIs) such as sertraline, fluoxetine, citalopram, escitalopram, paroxetine, and fluvoxamine are first-line treatments for depression, anxiety, OCD, PTSD, and panic disorder. They work by blocking the serotonin transporter so more serotonin stays active in the synapse. Cannabis contains many cannabinoids, principally THC and CBD, which act mainly on cannabinoid receptors but also brush up against the serotonin system and against the liver enzymes that metabolise medicines.
Two separate pathways matter here:
- Enzyme inhibition (pharmacokinetic). Cannabinoids inhibit several liver enzymes, including CYP2C19. Sertraline, citalopram, and escitalopram rely heavily on CYP2C19 to be cleared. With cannabis or CBD on board, the body clears these SSRIs more slowly, so their levels in the blood can drift higher than the prescribed dose was meant to produce.
- Serotonin stacking (pharmacodynamic). Cannabinoids appear to nudge certain serotonin receptors. Layered on top of an SSRI that is already raising serotonin tone, this added push can, in susceptible people, tip the system toward serotonin excess.
- Concentrate effect. Modern concentrates (vape distillate, dabs, shatter, wax) deliver far more THC per use than traditional flower. The recent reports of serotonin syndrome in people on serotonergic medicines have clustered around these high-potency products rather than occasional, low-potency use.
A 2024 case report in Australasian Psychiatry describes a young man on a serotonergic regimen (fluoxetine plus lithium) who presented repeatedly over a few weeks with features of serotonin syndrome, each episode tied to high-potency cannabis vape and dab use. It is a single case, not proof of frequency, but it illustrates the mechanism plausibly.
Why is this important?
Serotonin syndrome is a clinical emergency. It shows up as a combination of mental-status change (agitation, confusion, restlessness), autonomic instability (sweating, fever, fast pulse, diarrhoea, dilated pupils), and neuromuscular signs (tremor, muscle twitching, ankle clonus, rigidity). At its most severe it can cause dangerously high fever, muscle breakdown, and death. The great majority of people on an SSRI alone never experience it; the risk rises when a second serotonergic agent is added on top, and high-potency cannabis appears to be one such agent in rare cases.
Short of full serotonin syndrome, slowly rising SSRI levels can also surface as side effects people would not blame on cannabis: more nausea, jitteriness, insomnia, sexual dysfunction, headache, or paradoxical anxiety after starting or scaling up cannabis. Because the change is gradual, it is easy to misread it as "my depression coming back" and respond by raising the SSRI, the cannabis, or both, which only deepens the problem.
There is also a treatment-response concern. SSRIs need steady, consistent blood levels and weeks of receptor adaptation to work. Heavy cannabis use disturbs sleep architecture and blunts emotional reactivity in ways that overlap with depression itself, and it has been linked in observational studies to poorer SSRI response. Combining the two can leave you and your doctor unsure whether the medication is failing or whether cannabis is masking, mimicking, or worsening the illness.
What should you do?
The core principle is simple: be honest with your prescriber, lean toward lower-potency products, and treat warning signs as an emergency. Specific doses and switches should be decided with your doctor or pharmacist, not self-managed.
Before any change (or before your next appointment): Tell your prescriber about all cannabis use, including medical cannabis prescribed elsewhere and over-the-counter CBD. This is exactly the information that lets them monitor more closely or choose an SSRI less dependent on CYP2C19. There is nothing to be embarrassed about.
Every day, while you take both: Favour lower-potency forms over high-potency concentrates such as dab pens, distillate cartridges, shatter, and wax. Keep your cannabis use as steady and predictable as possible rather than spiking it, and do not raise your SSRI dose on your own to chase symptoms that feel like relapse.
After any change (new SSRI, dose change, or new/stronger cannabis product): Watch closely for the first several weeks as the medication settles, since that is when the picture is hardest to read. If agitation, confusion, sweating, fever, fast heart rate, tremor, muscle twitching, clonus, or diarrhoea appear, particularly within hours of cannabis use, stop the cannabis and seek emergency care, telling responders both substances you take.
Which specific products are affected?
On the medication side, the SSRIs include sertraline (Zoloft), fluoxetine (Prozac, Sarafem), citalopram (Celexa), escitalopram (Lexapro, Cipralex), paroxetine (Paxil, Pexeva), and fluvoxamine (Luvox). The sertraline, citalopram, and escitalopram group is most exposed to the enzyme effect because of their reliance on CYP2C19. The closely related SNRIs venlafaxine (Effexor), desvenlafaxine (Pristiq), and duloxetine (Cymbalta), as well as vortioxetine (Trintellix) and vilazodone (Viibryd), are also serotonergic and share much of the serotonin-stacking concern.
On the cannabis side, the interaction applies broadly to products containing THC or meaningful CBD, but the serotonin-syndrome reports concentrate around high-potency products: distillate vape cartridges, live-resin or rosin dabs, shatter, wax, and strong infused edibles. Hemp-derived CBD wellness products carry less acute serotonin-syndrome risk on their own but still inhibit CYP2C19 and can raise SSRI levels. Other serotonergic agents that add to the load, and that your prescriber should know about, include MAOIs, tramadol, dextromethorphan, St. John's wort, lithium, certain triptans, and MDMA.
The science behind it
The clearest signal comes from human case reports rather than large trials, so the evidence is suggestive rather than definitive.
- Nadeem and colleagues (Australasian Psychiatry, 2024; PMID 38058145) report a human case of serotonin syndrome, judged by recognised diagnostic criteria, recurring in a patient on a serotonergic regimen, with each episode linked to high-potency cannabis use.
- A pharmacogenomic human case report (PMC9815864) describes a person taking sertraline who developed cognitive dysfunction from hyponatremia attributed to a drug-drug-gene interaction with CBD in a reduced-function CYP2C19 metaboliser, directly illustrating CBD-driven elevation of an SSRI's effect.
- A review of CBD drug interactions for prescribers and pharmacists (Expert Review of Clinical Pharmacology, 2022) summarises the pharmacokinetic basis, including CBD's inhibition of CYP2C19 and the consequent potential to raise levels of co-administered substrates such as several SSRIs.
Together these support the mechanism and the direction of the interaction. What they do not provide is a reliable frequency or a dose threshold, which is why the practical advice is principle-based rather than numeric.
Frequently Asked Questions
Do I have to stop cannabis to take an SSRI?
Not necessarily, but your prescriber needs to know about it. They may keep both with closer monitoring, suggest a lower-potency product, or prefer an SSRI less dependent on CYP2C19. The decision is theirs to make with you.
Is CBD safer than THC here?
For serotonin syndrome specifically, CBD-only products carry less acute risk. But CBD still inhibits CYP2C19 and can raise SSRI levels, so it is not free of interaction. Mention CBD to your prescriber the same way you would mention THC.
How would I know if it is serotonin syndrome?
Look for a cluster of agitation or confusion, sweating, fever, fast heart rate, tremor, muscle twitching, ankle clonus, and diarrhoea, especially within hours of cannabis use. A cluster like that is an emergency; do not wait it out.
Why are concentrates singled out?
Concentrates such as dabs, shatter, and distillate cartridges deliver much more THC per use than flower, and the serotonin-syndrome reports have clustered around them. Lower-potency forms appear less likely to push the system that far.
Can cannabis make my antidepressant seem to stop working?
It can muddy the picture. Heavy cannabis disturbs sleep and emotional reactivity in ways that overlap with depression, and it has been linked to poorer SSRI response, so it can be hard to tell whether the medication is failing or being masked.
Should I raise my SSRI dose if I feel worse after using cannabis?
No, not on your own. Feeling worse may reflect the interaction rather than relapse, and raising the dose without telling your prescriber about cannabis can make things worse. Talk to them first.
Key takeaways
- Cannabis and SSRIs interact two ways: cannabinoids slow the liver enzymes (including CYP2C19) that clear several SSRIs, and they add to serotonin tone the SSRI is already raising.
- Most people on an SSRI will not develop serotonin syndrome, but case reports tie high-potency cannabis concentrates to it in people on serotonergic medicines.
- Sertraline, citalopram, and escitalopram are most exposed to the enzyme effect; SNRIs and other serotonergic drugs share the serotonin concern.
- Tell your prescriber about all cannabis and CBD use, favour lower-potency products, and review your full regimen with your doctor or pharmacist rather than self-adjusting doses.
- Treat a cluster of fever, sweating, tremor, agitation, fast heart rate, or clonus after cannabis use as an emergency.